Stock comparison
Mettler-Toledo International
Anbio Biotechnology
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
NNNN
Anbio Biotechnology
Market cap
$1.43B
Sector
Healthcare
Overall winner
Anbio Biotechnology NNNN
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | MTD | NNNN | Winner |
|---|---|---|---|
| Warren Buffett | 69B | 58C | MTD |
| Benjamin Graham | 65B | 87A | NNNN |
| Philip Fisher | 63C | 89A | NNNN |
| Peter Lynch | 66B | 95A | NNNN |
| Joel Greenblatt | 68B | 36D | MTD |
| Charlie Munger | 74B | 73C | MTD |
| Terry Smith | 70B | 72C | NNNN |
Side-by-side metrics
| Metric | MTD | NNNN |
|---|---|---|
| Market cap | $22.29B | $1.43B |
| P/E (TTM) | 25.3x | 171.9x |
| EV/EBIT | 21.6x | 212.9x |
| ROIC (TTM) | 36.09% | 21.48% |
| Gross margin | 57.79% | 87.06% |
| Net margin | 21.4% | 73.75% |
| Revenue CAGR 5y | 2.01% | 18.21% |
| EPS CAGR 5y | 6.12% | 58.42% |
| Debt / Equity | - | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
MTD leads on
- Debt / Equity-vs -+100%
- Market cap$22.29Bvs $1.43B+94%
- EV/EBIT21.6xvs 212.9x+90%
- P/E (TTM)25.3xvs 171.9x+85%
NNNN leads on
- EPS CAGR 5y58.42%vs 6.12%+90%
- Revenue CAGR 5y18.21%vs 2.01%+89%
- Net margin73.75%vs 21.4%+71%
- Gross margin87.06%vs 57.79%+34%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.